Independent Study Confirms Strong Efficacy Of Argent BioPharma’s ArtemiC™ Against Acute Respiratory Distress Syndrome (ARDS)

Argent BioPharma Ltd. announced promising results from an independent in vivo study of its lead immunomodulatory therapy, ArtemiC™ (CimetrA®), in a severe viral inflammatory model simulating Acute Respiratory Distress Syndrome (ARDS). The study was conducted by AMC Pharma USA in collaboration with the Botanical Medicine Research and Education Consortium (BMREC) at the University of South Florida and was fully financed independently. Published on August 20, 2025, the findings strengthen AMC Pharma’s commercial positioning and support expected U.S. and international demand under existing distribution agreements.

The trial tested ArtemiC™ in K18-hACE2 transgenic mice, a widely used model for severe viral infections. Results showed up to 85% survival in treated animals compared to 0% in untreated controls (p<0.001). ArtemiC™ significantly reduced viral loads in both lung and brain tissues while suppressing cytokine-driven inflammatory injury, a critical factor in morbidity. The therapy also enhanced antiviral efficacy, extending survival and demonstrating a 20–40% survival advantage in treated cohorts. 

Importantly, ArtemiC™ effectively mitigated cytokine storm responses triggered during the viral challenge, reinforcing its proposed role as a targeted anti-inflammatory and antiviral intervention in hyperinflammatory disease conditions such as ARDS. Argent BioPharma highlighted that these results provide a robust scientific foundation for future commercialization of ArtemiC™ in the U.S. and other territories.